Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Stattin, P; Soderberg, S; Hallmans, G; Bylund, A; Kaaks, R; Stenman, UH; Bergh, A; Olsson, T
   Leptin is associated with increased prostate cancer risk: A nested case-referent study
   JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
   
   P. Stattin et al., "Leptin is associated with increased prostate cancer risk: A nested case-referent study", J CLIN END, 86(3), 2001, pp. 1341-1345
2. Bylund, A; Zhang, JX; Bergh, A; Damber, JE; Widmark, A; Johansson, A; Adlercreutz, H; Aman, P; Shepherd, MJ; Hallmans, G
   Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate adenocarcinoma in nude mice
   PROSTATE
   
   A. Bylund et al., "Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate adenocarcinoma in nude mice", PROSTATE, 42(4), 2000, pp. 304-314
3. Stattin, P; Bylund, A; Rinaldi, S; Biessy, C; Dechaud, H; Stenman, UH; Egevad, L; Riboli, E; Hallmans, G; Kaaks, R
   Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study
   JOURNAL OF THE NATIONAL CANCER INSTITUTE
   
   P. Stattin et al., "Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study", J NAT CANC, 92(23), 2000, pp. 1910-1917
4. Bylund, A; Stattin, P; Widmark, A; Bergh, A
   Predictive value of bcl-2 immunoreactivity in prostate cancer patients treated with radiotherapy
   RADIOTHERAPY AND ONCOLOGY
   
   A. Bylund et al., "Predictive value of bcl-2 immunoreactivity in prostate cancer patients treated with radiotherapy", RADIOTH ONC, 49(2), 1998, pp. 143-148